Home » Topics » BioWorld Science

BioWorld Science
RSS

Unum provides update on phase I study of ACTR-707 plus trastuzumab

Jan. 30, 2020

Positive preliminary data from first patient in diverticulosis pilot trial of PGLG

Jan. 30, 2020

Spring Bank discontinues development of inarigivir and all HBV programs

Jan. 30, 2020

AgeX Therapeutics collaborates with Japanese biopharma to generate hypoimmunogenic cells

Jan. 30, 2020

Erleada receives extended approval in Europe for metastatic hormone-sensitive prostate cancer

Jan. 30, 2020

FDA approves Monoferric injection for the treatment of iron deficiency anemia

Jan. 30, 2020

Novel cynomolgus macaque model for Sudan virus disease

Jan. 30, 2020

Dosing initiated in first-in-human study of IK-175

Jan. 30, 2020

Snake venom organoid gives toxin insights

Jan. 30, 2020

Avacta demonstrates proof of concept for TMAC platform in animal model of cancer

Jan. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...